– USA, AZ – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced the appointment of Chris Kiritsy to its Board of Directors.
“Chris’s considerable experience in the pharmaceutical industry and breadth and depth of expertise in both corporate development and finance will be tremendous assets to HTG, particularly as we continue to evolve our therapeutics business. We are delighted to welcome him to our Board of Directors,” said CEO, John Lubniewski.
About Christopher Kiritsy
Currently the Managing Member of Precision Kapital, LLC, a private investment and advisory firm, Chris Kiritsy co-founded Arisaph Pharmaceuticals, Inc. and served as its President and CEO until 2018. At Arisaph, Mr. Kiritsy evolved the drug discovery organization from its initial academic orientation into a clinical development enterprise, taking several cardiometabolic products into clinical development.
“HTG’s proprietary technology has the potential to significantly improve drug discovery, with the ability to reduce risk in the current drug development process and to identify potential problems, such as lack of efficacy or toxicity issues, much earlier and with far less downstream investment,” said Mr. Kiritsy. “I am delighted to be joining the Board at this exciting time for HTG and for the opportunity to leverage my experiences to help the company realize its vision to be an innovator in therapeutic drug development.”
Before Arisaph, Mr. Kiritsy served as EVP, Corporate Development and CFO of Kos Pharmaceuticals, Inc. (Kos), where he played a key operating role in the success of Kos’s Niaspan® franchise, and in building the company from a start-up to a highly profitable, publicly traded, fully integrated company. At Kos, which was acquired by Abbott Laboratories in 2006, he spearheaded more than 10 major corporate development transactions and raised approximately $500 million in public equity, including Kos’s initial public offering.
A graduate of Bowdoin College, Mr. Kiritsy also earned an M.B.A. from Boston University. In addition to HTG, he serves on the Board of Directors of Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), where he is Chair of the audit and compensation committees.
About HTG
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics, and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery.
For more information: https://www.htgmolecular.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
